Cat. No. | Product name | CAS No. |
DC9395 |
AT7519 (trifluoroacetate)
AT7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; less potent to CDK3 and little active to CDK7. |
1431697-85-6 |
DC7070 |
AT9283
Featured
AT9283 is a small molecule a multi-targeted inhibitor with of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), Jak2 and Jak3, aurora A and B, respectively. |
896466-04-9 |
DC7367 |
AZ-960
AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3. |
905586-69-8 |
DC7060 |
AZD1152
Featured
AZD1152 (barasertib), pro-drug of barasertib-hQPA, is a selective Aurora B kinase inhibitor, AZD1152 inhibited the proliferation various types of human leukemia cells with an IC50 ranging from 3 nM to 40 nM. |
722543-31-9 |
DC10774 |
AZD5153
Featured
AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor. |
1869912-39-9 |
DC2013 |
Bafetinib (INNO-406)
Featured
Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM and 19 nM, respectively. |
859212-16-1 |
DC10376 |
BAY-1143572
BAY 1143572 is a highly selective, potent and orally available inhibitor of PTEFb/CDK9; inhibits the proliferation of AML cell lines with a median IC50 of 385 nM. |
1414943-88-6 |
DC11719 |
BAY-1436032
BAY-1436032 (BAY1436032) is a potent, selective, orally available inhibitor of pan-mutant IDH1 with IC50 of 15 nM for both IDH1 R132H and R132C, respectively. |
1803274-65-8 |
DC10526 |
BAY-1895344 HCl(Elimusertib)
Featured
BAY-1895344 is a potent and selective ATM inhibitor. BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride. |
1876467-74-1 |
DC10448 |
Belizatinib(TSR-011)
Featured
Belizatinib(TSR-011) is an orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. |
1357920-84-3 |
DC10335 |
BGB-3111
BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor. |
1633350-06-7 |
DC5194 |
NVP-BGJ398(Infigratinib)
Featured
BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2. |
872511-34-7 |
DC7083 |
Bi 2536
Featured
BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM, BI2536 shows 4- and 11-fold greater selectivity against Plk2 and Plk3; BI2536 also is a BRD4 inhibitor(IC50= 25 nM). |
755038-02-9 |
DC5154 |
BKM120 (NVP-BKM120, Buparlisib)
Featured
BKM120 is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. |
944396-07-0 |
DC11862 |
BMS-906024
BMS-906024 is a highly potent, selective inhibitor of γ-secretase mediated signaling of Notch1/2/3/4 receptors with IC50 of 1.6/0.7/3.4/2.9 nM, respectively. |
1401066-79-2 |
DC1027 |
Bortezomib (Velcade,MG-341,PS-341)
Featured
Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM. |
179324-69-7 |
DC10648 |
CA4948-Analog
Featured
CA4948-Analog is an analog of Emavusertib. It has similar property to CA-4948, which is a potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. It was reported in patent WO 2015104688. Emavusertib, also known as CA-4948 i |
1801343-74-7 |
DC5068 |
Idelalisib (CAL-101,GS-1101)
Featured
CAL-101 is a selective p110δ inhibitor with IC50 of 2.5 nM; shown to have 40- to 300-fold greater selectivity for p110δ thanp110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. |
870281-82-6 |
DC1002 |
Carfilzomib (PR-171)
Featured
Carfilzomib is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells,showed potent activity against COVID-19(SARS-COV-2). |
868540-17-4 |
DC8840 |
CB-5083
Featured
CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models . |
1542705-92-9 |
DC8377 |
CC-115
Featured
CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity. |
1228013-15-7 |
DC10146 |
CC-122(Avadomide)
Featured
CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity.CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL. |
1015474-32-4 |